The company posted an 11 percent year-over-year decline in OVA1 sales but more than doubled its average revenue per test, to $301 from $143 in Q4 2015.
The deal adds germline mutation information to the tumor sequencing, proteomic, and phosphoproteomic data Perthera currently uses to guide patient therapy.
Developed by a team at Babraham and Karolinska institutes, the panel could improve stem cell resetting methods and research in the field more generally.
The company has contracted with EKG Sales Associates for life science lead generation and hired two new sales directors.
A company researcher said the new structure could provide the chemical diversity needed to build a set of reagents targeting the full human proteome.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.
Some science companies will be taking part in next month's March for Science, Fortune reports.
In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.
Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.